Trial reportDrug design, development and therapy2026
Esketamine Accelerates Emergence from Propofol Anesthesia in Patients Undergoing Laparoscopic Gynecological Surgery: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: While esketamine has shown promise in enhancing the quality of anesthesia recovery, its effect on a critical recovery endpoint-extubation time-has yielded inconsistent results across clinical studies. Therefore, this study investigated the effect of esketamine on extubation time in patients undergoing general anesthesia. Methods: In this single-center, randomized, double-blind, placebo-controlled trial (RCT), we enrolled 154 patients scheduled for elective laparoscopic hysterectomy. Patients were randomly assigned to receive either intravenous esketamine (a bolus of 0.2 mg/kg at induction, followed by a continuous infusion of 0.125 mg/kg/h) or an equivalent volume of normal saline as placebo. For all patients, a transversus abdominis plane (TAP) block was performed with 0.25% ropivacaine at the end of surgery. The primary analysis was conducted according to a modified intention-to-treat (mITT) principle, including all randomized patients who received the allocated intervention and had the primary outcome assessed. The sample size was calculated to provide 90% power to detect a 4-minute difference in extubation time. The primary outcome was the time to extubation in the post-anesthesia care unit (PACU). The Bonferroni correction was applied to secondary outcomes to adjust for multiple comparisons. Results: A total of 141 patients completed the study (Esketamine group: n=70; Control group: n=71). Compared to the control group, the esketamine group had a significantly shorter extubation time (23.2 ± 5.2 minutes vs. 28.5 ± 5.3 minutes; mean difference -5.3 minutes, 95% CI: -7.1 to -3.5; P<0.001). PACU stay duration was also reduced (60.2 ± 7.3 minutes vs. 65.8 ± 6.9 minutes; P<0.001). Furthermore, patients receiving esketamine reported lower postoperative pain scores and required less opioid consumption, with no significant increase in adverse effects. Conclusion: Adjunctive low-dose esketamine during propofol-based total intravenous anesthesia significantly shortens extubation time and PACU stay, reduces intraoperative opioid consumption, and no significant increase in adverse effects was observed in this cohort. The reduction in postoperative pain scores did not remain significant after Bonferroni correction and requires further confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.